NL-OMON36159
Recruiting
Not Applicable
Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid malignancies - Intratumoral kinase inhibitor concentrations in advanced cancer patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- alle vormen van gevorderde, dwz inoperabele of uitgezaaide, solide tumoren
- Sponsor
- Vrije Universiteit Medisch Centrum
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Advanced solid malignancy, minimum age 18 years, indication for palliative treatment, measurable disease with at least one lesion accessable for biopsy
Exclusion Criteria
- •Cardiovascular conditions including congestive heartfailure NYHA class \>2, recent myocardial infarction or uncontrolled coronary artery disease, cardiac arrhythmias requiring anti\-arrhythmic therapy, uncontrolled hypertension; uncontrolled infections; serious non\-healing wound, ulcer or bone fracture, pregnant or breast feeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A pilot study to measure the pressure of fluid present around cells of various solid cancer tumors.Health Condition 1: C00-D49- NeoplasmsCTRI/2021/08/035470Tata Memorial Centre
Not yet recruiting
Not Applicable
Pilot study to determine the intraTUMORal OsImertinib concentration in patients with peritoneal metastasizeD colorectal cancer (TUMOROID study)Colorectal cancercolon cancer1001799110017998NL-OMON51641Radboud Universitair Medisch Centrum10
Completed
Not Applicable
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CancerAdvanced Solid TumorsNCT01636908Amsterdam UMC, location VUmc43
Terminated
Phase 1
Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell CarcinomaACTRN12619001407189QBiotics Group Limited19
Unknown
Phase 1
To study the Safety, Tolerability and Tumour Response when treated with drug Tigilanol Tiglate administered intratumourally in Patients with Head and Neck Squamous Cell Carcinoma.Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxCTRI/2019/11/022032QBiotics Group Limited13